View in EDS HTML Full Text PDF Full Text

[18F]-fluoromisonidazole (FMISO) PET/MRI hypoxic fraction distinguishes neuroinflammatory pseudoprogression from recurrent glioblastoma in patients treated with pembrolizumab.

Saved in:
Bibliographic Details
Title: [18F]-fluoromisonidazole (FMISO) PET/MRI hypoxic fraction distinguishes neuroinflammatory pseudoprogression from recurrent glioblastoma in patients treated with pembrolizumab.
Authors: Barajas RF Jr; Department of Radiology, Neuroradiology Section, Oregon Health & Science University, Portland Oregon, USA.; Knight Cancer Institute Translational Oncology Program, Oregon Health & Science University, Portland, Oregon, USA., Ambady P; Neuro-Oncology and Blood-Brain Barrier Program, Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA., Link J; Center for Radiochemistry Research, Oregon Health & Science University, Portland, Oregon, USA., Krohn KA; Center for Radiochemistry Research, Oregon Health & Science University, Portland, Oregon, USA., Raslan A; Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA., Mallak N; Advanced Imaging Research Center, Oregon Health & Science University, Portland Oregon, USA., Woltjer R; Department of Pathology, Oregon Health & Science University, Portland, Oregon, USA., Muldoon L; Neuro-Oncology and Blood-Brain Barrier Program, Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA., Neuwelt EA; Neuro-Oncology and Blood-Brain Barrier Program, Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.; Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA.; Office of Research and Development, Portland Veterans Affairs Medical Center, Portland, Oregon, USA.
Source: Neuro-oncology practice [Neurooncol Pract] 2022 Mar 09; Vol. 9 (3), pp. 246-250. Date of Electronic Publication: 2022 Mar 09 (Print Publication: 2022).
Publication Type: Case Reports; Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101640528 Publication Model: eCollection Cited Medium: Print ISSN: 2054-2577 (Print) Linking ISSN: 20542577 NLM ISO Abbreviation: Neurooncol Pract Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35601969
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: [<superscript>18</superscript>F]-fluoromisonidazole (FMISO) PET/MRI hypoxic fraction distinguishes neuroinflammatory pseudoprogression from recurrent glioblastoma in patients treated with pembrolizumab.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Barajas+RF+Jr%22">Barajas RF Jr</searchLink>; Department of Radiology, Neuroradiology Section, Oregon Health & Science University, Portland Oregon, USA.; Knight Cancer Institute Translational Oncology Program, Oregon Health & Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Ambady+P%22">Ambady P</searchLink>; Neuro-Oncology and Blood-Brain Barrier Program, Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Link+J%22">Link J</searchLink>; Center for Radiochemistry Research, Oregon Health & Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Krohn+KA%22">Krohn KA</searchLink>; Center for Radiochemistry Research, Oregon Health & Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Raslan+A%22">Raslan A</searchLink>; Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Mallak+N%22">Mallak N</searchLink>; Advanced Imaging Research Center, Oregon Health & Science University, Portland Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Woltjer+R%22">Woltjer R</searchLink>; Department of Pathology, Oregon Health & Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Muldoon+L%22">Muldoon L</searchLink>; Neuro-Oncology and Blood-Brain Barrier Program, Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Neuwelt+EA%22">Neuwelt EA</searchLink>; Neuro-Oncology and Blood-Brain Barrier Program, Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.; Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA.; Office of Research and Development, Portland Veterans Affairs Medical Center, Portland, Oregon, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101640528%22">Neuro-oncology practice</searchLink> [Neurooncol Pract] 2022 Mar 09; Vol. 9 (3), pp. 246-250. <i>Date of Electronic Publication: </i>2022 Mar 09 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Case Reports; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101640528 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2054-2577 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220542577%22">20542577 </searchLink><i>NLM ISO Abbreviation: </i>Neurooncol Pract <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35601969
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/nop/npac021
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 246
    Titles:
      – TitleFull: [18F]-fluoromisonidazole (FMISO) PET/MRI hypoxic fraction distinguishes neuroinflammatory pseudoprogression from recurrent glioblastoma in patients treated with pembrolizumab.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Barajas RF Jr
      – PersonEntity:
          Name:
            NameFull: Ambady P
      – PersonEntity:
          Name:
            NameFull: Link J
      – PersonEntity:
          Name:
            NameFull: Krohn KA
      – PersonEntity:
          Name:
            NameFull: Raslan A
      – PersonEntity:
          Name:
            NameFull: Mallak N
      – PersonEntity:
          Name:
            NameFull: Woltjer R
      – PersonEntity:
          Name:
            NameFull: Muldoon L
      – PersonEntity:
          Name:
            NameFull: Neuwelt EA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 03
              Text: 2022 Mar 09
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 2054-2577
          Numbering:
            – Type: volume
              Value: 9
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Neuro-oncology practice
              Type: main
ResultId 1